Sorrento's Human Derived Mesenchymal Stem Cells Achieves 100% Discharge Rate In Critically-Ill COVID-19 Patients

Sorrento Therapeutics Inc (NASDAQ: SRNE) has announced data from its Phase 1b study of human allogeneic adipose-derived mesenchymal stem cells (COVI-MSC) infusions to treat COVID-19 induced acute respiratory failure (ARD) or acute respiratory distress syndrome (ARDS).
The study met its primary objective to demonstrate the safety of intravenous infusion of allogeneic adipose MSC cells in patients with COVID-19-induced ARD or ARDS.
Subjects were administered COVI-MSCs every other day for up to three infusions for a total of 1 x 106 cells/kg, with patients being followed for 28 days following the final infusion.
A total of 10 patients were enrolled, and all were discharged from the hospital to home within three days of their last infusion.
At baseline, all patients required oxygen supplementation. All patients had various medical co-morbidities in addition to obesity.
The 10th patient had been under treatment for nearly two weeks without improvement and was discharged after the second COVI-MSC infusion.
Sorrento will be working with the FDA shortly once the whole dataset is available to plan a placebo-controlled pivotal study to support an emergency use authorization submission.
Price Action: SRNE shares are up 2.3% at $7.66 in market hours on the last check Tuesday.

To add Benzinga News as your preferred source on Google, click here.